Eli Lilly's Taltz beats J&J's Tremfya in psoriasis head-to-head — but the marketing brawl is just beginning
Eli Lilly has come out swinging at J&J, staking out its challenger position in a crowded battle of plaque psoriasis blockbusters.
In a Phase IV …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
